AIP2 Inhibitors
AIP2 inhibitors are a class of chemical compounds that target the activity of the Apoptosis Inhibitory Protein 2 (AIP2), a regulatory protein involved in various intracellular processes. AIP2, also known as Cellular Inhibitor of Apoptosis Protein 2 (cIAP2), is part of the inhibitor of apoptosis proteins (IAPs) family, which are characterized by their ability to bind to caspases and other signaling molecules to modulate apoptotic and non-apoptotic pathways. AIP2 contains specific structural domains such as baculoviral IAP repeat (BIR) domains and a really interesting new gene (RING) domain. These domains play a crucial role in regulating protein-protein interactions, ubiquitination processes, and the modulation of intracellular signaling pathways, particularly those associated with cell survival, differentiation, and immune responses. By inhibiting AIP2, chemical compounds can influence these pathways, affecting processes like ubiquitin-mediated protein degradation and the control of inflammatory signaling cascades.
Chemically, AIP2 inhibitors are diverse and often consist of small molecules designed to disrupt the protein's functional domains. These inhibitors typically target the BIR domains to block AIP2's interaction with caspases or interfere with the RING domain to prevent its E3 ligase activity. The structure of these inhibitors often involves mimicking endogenous proteins or ligands that naturally regulate AIP2 function. Some inhibitors operate by promoting the auto-ubiquitination and subsequent degradation of AIP2, leading to alterations in key intracellular signaling mechanisms. The development of AIP2 inhibitors requires a deep understanding of the conformational dynamics of the protein and the specific interactions at its active sites, making them an intriguing subject for research in biochemistry and molecular biology.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A-769662, an AMP-activated protein kinase (AMPK) activator, indirectly inhibits AIP2. By activating AMPK, A-769662 influences the AMPK/mTOR signaling pathway. AIP2 is known to interact with mTOR, and A-769662's action results in the inhibition of mTOR, consequently modulating AIP2 levels. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine, an inhibitor of autophagy, indirectly influences AIP2 by targeting the autophagic pathway. AIP2 is involved in autophagic processes, and 3-Methyladenine inhibits the formation of autophagosomes by suppressing class III phosphatidylinositol 3-kinase (PI3K). This inhibition disrupts the autophagic flux, impacting AIP2 turnover and activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2, a Src family kinase inhibitor, indirectly modulates AIP2 levels by affecting the Src signaling pathway. AIP2 is known to interact with Src, and PP2 inhibits Src kinase activity, leading to alterations in the signaling cascade. This disruption influences AIP2 expression, providing an indirect inhibitory effect on the protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a selective JNK inhibitor, indirectly influences AIP2 by targeting the JNK signaling pathway. AIP2 is a substrate of JNK, and SP600125 disrupts JNK activation, affecting the phosphorylation of AIP2. This inhibition leads to altered AIP2 activity, providing an indirect inhibitory effect on the protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a fungal metabolite, indirectly modulates AIP2 by inhibiting the PI3K/Akt signaling pathway. AIP2 is known to interact with Akt, and Wortmannin blocks PI3K activity, preventing Akt activation. This disruption influences AIP2 levels and activity, providing an indirect inhibitory effect on the protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a synthetic inhibitor of PI3K, indirectly inhibits AIP2 by disrupting the PI3K/Akt signaling pathway. AIP2 is known to interact with Akt, and LY294002 blocks PI3K activity, preventing Akt activation. This disruption influences AIP2 levels and activity, providing an indirect inhibitory effect on the protein. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a pyridinyl imidazole compound, indirectly modulates AIP2 by inhibiting p38 MAP kinase. AIP2 is known to interact with p38 MAP kinase, and SB203580 disrupts the MAPK signaling pathway. This disruption influences AIP2 expression, providing an indirect inhibitory effect on the protein. | ||||||
A 922500 | 959122-11-3 | sc-203793 | 10 mg | $270.00 | 2 | |
A-922500, an inhibitor of fatty acid amide hydrolase (FAAH), indirectly influences AIP2 by affecting endocannabinoid signaling. AIP2 is known to interact with endocannabinoid receptors, and A-922500 inhibits FAAH, leading to increased endocannabinoid levels. This disruption in endocannabinoid signaling influences AIP2 expression, providing an indirect inhibitory effect on the protein. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a specific MEK inhibitor, indirectly influences AIP2 by targeting the MAPK/ERK signaling pathway. AIP2 is known to interact with components of the MAPK/ERK pathway, and PD98059 blocks the activation of MEK, leading to altered signaling. This disruption influences AIP2 expression, providing an indirect inhibitory effect on the protein. | ||||||